Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 26;13:935444. doi: 10.3389/fmicb.2022.935444

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Baldwin, Reese, Larsen, Pecor, Brown, Granger, Podell, Fox, Reed and Coler.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Kaplan–Meier survival curves for each intervention. A subset of 11 mice per group were followed for survival following Mtb H37Rv infection, treatment for 8 weeks with Isoniazid, Rifampin, and Pyrazinamide in the drinking water, and therapeutic immunization with ID93 vaccines 4 weeks after the start of drug treatment. 95% CI is indicated in the shaded region on each side of the Kaplan–Meier survival curve. Indicated p values were determined using Cox Proportional Hazard models and are relative to the unimmunized group. N = 11 mice per group, except for ID93 + GLA-LSQ2 and ID93 + GLA-LSQ3 (n = 9 mice/group); (A) Drug treatment + ID93 + GLA-AF; (B) Drug treatment + ID93 + GLA-LS2; (C) Drug treatment + ID93 + GLA-LS3; (D) Drug treatment + ID93 + GLA-LSQ2; (E) Drug treatment + ID93 + GLA-LSQ3; and (F) Drug treatment only (unimmunized).